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Both isomers of (E)-2,3_methanophenylalanine (V EPhe), a sterically restricted amino acid, were incorporated into pep- 
tides in order to examine their possible enzyme inhibitory activity. Both (2R,3S)- and (2S,3R)- VEPhe-Phe(or Leu)-OMe 
were found to inhibit effectively the hydrolysis of Ac-Tyr-OEt by chymotrypsin in a competitive manner. The ester groups 
of these dipeptides were quite resistant o chymotrypsin hydrolysis, and the V EPhe-Phe peptide bond was also entirely 
stable. The inhibition constant (Ki) of the most potent dipeptide of H-(2R,3S)-VEPhe-Phe-OMe was 0.16 mM at 25°C. 
The inhibitory action of VPhe-containing peptides was found to depend on the configuration of the V Phe residue. The 
electrophilic nature of the cyclopropane ring which is conjugated with both the phenyl ring and the ester carbonyl group 
appears to be relevant o the inhibitory activity. Fully irreversible inactivation of chymotrypsin was achieved by its incu- 
bation with H-(2R,3S)-VEPhe-Leu-OMe. An enzyme carboxylate group is thought to be responsible for nucleophilic at- 
tack on the cyclopropane ring leading to irreversible inactivation. 
Enzyme inhibition; Phenylalanine; Amino acid isomer 
1. INTRODUCTION 
Various chymotrypsin-like proteases have 
recently been discovered in cells from pathological 
lesions such as those present in carcinogenesis [l], 
muscular dystrophy [2], and rheumatoid arthritis 
[3]. For instance, a chymotrypsin-like intracellular 
protease involved in the expression of a transform- 
ed phenotype in in vivo carcinogenesis was isolated 
from mouse embryo fibroblast cells. It was 
characterized using the Bowman-Birk inhibitor, 
chymostatin, and TPCK. Interestingly, these in- 
hibitors per se are anticarcinogenic [l]. A limited 
number of compounds are known, however, as 
highly specific inhibitors of chymotrypsin or 
chymotrypsin-like enzymes. Even such specific in- 
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hibitors as chymostatin, aldehyde or ketone type 
compounds, and boronic acid derivatives have 
disadvantages in kinetic and physiological in- 
vestigations because of their poor water solubility 
and high toxicity [4]. It is thus important to design 
and synthesize new inhibitors which have proper- 
ties without these drawbacks. 
The interaction between a specific low molecular 
weight ligand and a protein receptor is usually very 
strong. This can be increased further by rigidifying 
the ligand so that it fits more tightly to the recep- 
tor. Since the interaction between ligand and 
receptor is essentially the same as that between en- 
zyme and substrate or inhibitor, it is possible to 
obtain powerful low molecular inhibitors by 
designing a peptide with rigid structure. In the pre- 
sent study, we have designed dipeptides containing 
2,3_methanophenylalanine, designated as V Phe, 
as potential enzyme inhibitors (fig.1). 
2,3-Methanoamino acids ( VAA) are structural- 
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Fig. 1. Chemical structure of V EPhe-containing dipeptides. A, 
H-(2R,3S)- VEPhe-Phe(or Leu)-OH (or OMe); B, H- 
(2S,3R)- VEPhe-Phe(or Leu)-OH (or OMe). 
ly constrained, having only two possible side chain 
rotatory angles, x1 = 0” and 120”, which corre- 
spond to the Z- and E-configurations, respectively. 
In addition, the incorporation of V AA into a pep- 
tide constrains effectively the proximal peptide 
conformation due to the small 4 and # angles at 
the VAA conformational energy minima. cu,& 
Dehydroamino acids (AAA) are another in- 
teresting type of sterically restricted compounds 
which also increase peptide rigidity due to limita- 
tion of 4 and $ angles. Utilizing these VAA and 
AAA as constituents, various agonist and an- 
tagonist analogs of biologically active peptides 
have been reported [5-81. We have recently found 
that enkephalin analogs containing VAA and 
AAA are strongly resistant to enzymes such as 
chymotrypsin and carboxypeptidase Y [7,8]. Since 
these structurally constrained amino acid 
derivatives have additional interesting electrophilic 
properties due to the r-character of cyclopropane 
ring, we thought that the combined effects of con- 
formational rigidity and electrophilicity might 
lead, not only to stabilization toward enzyme 
cleavage, but also to enzyme inhibition. Herein, we 
describe the inhibitory activity of some VAA 
dipeptides on the serine protease, chymotrypsin, 
and suggest a possible inhibitory mechanism. 
2. MATERIALS AND METHODS 
2.1. Materials 
The synthesis of 2,3-methanophenylalanine and H-(2R,3S)- 
or (2S,3R)- VEPhe-Leu-OH (or OMe) were reported previously 
[8]. Optically pure dipeptide derivatives, Cbz-(2R,3S)- and Cbz- 
(2S,3R)- PEPhe-Phe-OMe, were obtained from an isomeric 
mixture of Cbz-( + )- VEPhe-Phe-OMe by separation on a silica 
gel column. The benzyloxycarbonyl group (Cbz) was removed 
with trifluoroacetic acid in the presence of thioanisole to avoid 
the destruction of the cyclopropane ring [8]. The purity of the 
water soluble dipeptide esters was verified by HPLC, CD and 
‘H-NMR measurements. 
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Bovine chymotrypsin was purchased from Worthington 
Biochemical Co. (Freehold, NJ) and Ac-Tyr-OEt was purchas- 
ed from the Peptide Institute Inc. (Osaka). 
2.2. Enzyme assays 
The stability of the synthetic peptides to chymotrypsin 
hydrolysis was monitored by HPLC at certain time intervals. 
The peptide (1 mM) was incubated in phosphate buffer (total 
volume, 3.0 ml; pH 7.0) with chymotrypsin (1.3 cg/ml) at 
25°C. An aliquot (10 ~1) of the incubation mixture was added 
to acetic acid (lo&, and the solution was injected into the 
HPLC to determine the 070 hydrolysis. Analytical HPLC was 
performed on a Hitachi no.3063 ODS reversed-phase column (4 
x 150 mm) in 0.1% trifluoroacetic acid with a linear gradient 
of acetonitrile (lo-60%) for 60 min. 
V Phe-containing dipeptides were assayed for chymotrypsin 
inhibition using Ac-Tyr-OEt as a substrate. Inhibition constants 
(Ki) were determined by Dixon plots [9] and are summarized in 
table 1. 
2.3. ‘H-Nh4R measurements 
All ‘H-NMR spectra were recorded on a JEOL JNM-GX-270 
spectrometer (270 MHz) and the chemical shifts were determin- 
ed using tetramethylsilane as an internal standard at 30°C. The 
NMR samples contained 6 mg of peptide in 0.5 ml DMSO-de 
and the signal assignments were made using two-dimensional 
COSY and NOE experiments. 
3. RESULTS AND DISCUSSION 
The compounds examined have both peptide 
and ester bonds, and we examined the enzymatic 
stability of these linkages prior to the inhibition 
assay. Fig.2 shows the stability of VPhe- 
containing peptides to chymotrypsin. While Ac- 
Tyr-OEt was hydrolyzed completely within 
15 min, H- VZPhe-OMe was fully resistant o the 
enzyme, showing no hydrolysis even after 2 h 
(fig.2) indicating that the linkage at the carbonyl 
side of the VPhe residue was completely stable. 
The dipeptide, H- VEPhe-Leu-OMe, was also quite 
stable since only 15% of acid, H- VEPhe-Leu-OH, 
after 1 h and no amino acids ( PEPhe and Leu) 
were detected indicating that the peptide bond was 
unhydrolyzed. The hydrolysis of the ester bond 
during the first 5 min, which is the time necessary 
for the inhibition assay, was almost negligible. 
These results clearly confirm the strong resistance 
of VPhe peptides to hydrolysis by chymotrypsin 
[7,81. 
When these peptides were assayed for inhibition 
of chymotrypsin, we found that, as expected, they 
did inhibit the enzyme. By analyses of Dixon plots, 
the inhibition was found to be competitive, with 
inhibition Ki values of 0.16-1.3 mM (table 1). 
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Fig.2. Chymotrypsin hydrolysis of V Phe-containing 
compounds. (m) Ac-Tyr-OEt; (o--o) H-(2R,3S)- PEPhe- 
Leu-OMe; (A--A) H- V EPhe-OMe. 
Among the peptides tested, H-(2R,3S)- VPhe-Phe- 
OMe was the best with Ki = 0.16 mM, while H- 
(2S,3R)- VPhe-Leu-OH showed no inhibition. 
Since H- V Phe-OMe inhibits Ac-Tyr-OEt hydro- 
lysis effectively while the corresponding free acid 
does not (table l), a peptide or ester bond at the 
carbonyl side of V Phe appears to be necessary for 
its interaction with chymotrypsin. 
The dipeptides synthesized in the present study 
possess two aromatic or hydrophobic moieties, 
either of which possibly occupies the chymotrypsin 
Sr site adjacent to the catalytic site. If VEPhe’ fits 
the Si hydrophobic pocket, inhibition of Ac-Tyr- 
OEt hydrolysis may be caused by both the steric 
and electrophilic character of VEPhe moiety. The 
rigidly fixed phenyl ring may energetically favor 
Table 1 
Ki values of inhibitors containing 2,3_methanophenylalanine 
Inhibitors Ki (mM) 
H-(2R,3S)- VEPhe-Phe-OMe 0.16 
H-(2S,3R)- VEPhe-Phe-OMe 0.60 
H-(2R,3S)- VEPhe-Phe-OH 0.60 
H-(2S,3R)- V EPhe-Phe-OH 1.4 
H-(2R,3S)- VEPhe-Leu-OMe 0.30 
H-(2S,3R)- VEPhe-Leu-OMe 1.3 
H-(2R,3S)- VEPhe-Leu-OH 0.75 
H-(2S,3R)- VEPhe-Leu-OH no inhibition 
H-( f )- V EPhe-OMe 0.43 
H-( f )- V EPhe-OH no inhibition 
H-( f )- V’Phe-OMe 0.36 
H-( + )- V’Phe-OH no inhibition 
the interaction with the enzyme Sr site. However, 
in the case of the simple amino acid derivatives, 
H- VZPhe or VEPhe-OMe, there was essentially 
no difference in the inhibition potency of the two 
stereoisomers (table l), a fact seemingly inconsis- 
tent with the above ‘fit’ argument. 
When Phe’ or Leu2 occupies the Sr site, other 
structural elements stabilizing the enzyme- 
inhibitor complex should exist. When the inhibi- 
tion potencies are considered in light of the con- 
figurations of the VPhe residue, changes in the 
amino acid at position 2, and changes in carboxylic 
acid function, the following points became clear: 
(i) (2R,3S)-configuration of V EPhe is preferred to 
the (2S,3R)-configuration, (ii) Phe’ is more 
favorable than Leu2, and (iii) the methyl ester is 
more effective than free acid. When all three 
favorable conditions are met, the most potent in- 
hibitor is obtained, indicating that it is likely that 
the amino acid at position 2, namely Phe’ or Leu2, 
is the residue interacting with the chymotrypsin Sr 
site rather than the VPhe in the l-position. 
‘H-NMR spectra of the series of H- PEPhe-Leu 
dipeptides discussed here showed remarkable dif- 
ferences between the (2R,3S)- and (2S,3R)-isomers 
and between the methyl ester and free acid, not on- 
ly in the chemical shifts of VPhe signals but also 
those in the Leu’ side chain. Detailed conforma- 
tional analysis from NMR studies suggested that 
the Leu2 side chain of (2R,3S)- VEPhe peptide is 
more strongly fixed than that of the 
(2S,3R)- VEPhe compound and this rigidity may 
be related to the somewhat greater (4 times) in- 
hibitory activity of the former. The NMR spec- 
trum of H-(2S,3R)- VPhe-Leu-OH, which has no 
inhibitory activity, was completely different from 
that of the other peptides. The X-ray structure of 
the (2R,3S)-dipeptide ester reported earlier [lo] 
shows a remarkable twist of the cyclopropane ring 
(the dihedral angle between the carbonyl and 
phenyl groups is 10.7’ instead of the theoretical 
0’) possibly weakening the ring and increasing the 
ease with which it is opened by nucleophiles. 
Details of the conformational analyses by NMR 
will be reported elsewhere. 
Suckling et al. [l 1,121 recently reported the par- 
tial irreversible inhibition of carboxypeptidase A 
by cyclopropane derivatives and suggested that en- 
zyme nucleophiles may attack the electrophilic 
cyclopropane ring of an inhibitor. As a 
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Fig.3. Chymotrypsin activity in Ac-Tyr-OEt hydrolysis after 
incubation with and without VEPhe-containing dipeptide 
inhibitor. a, enzyme preincubated with H-(2R,3S)- PEPhe-Leu- 
OMe for 48 h; b, enzyme preincubated without inhibitor; c, 
enzyme plus inhibitor not preincubated; d, enzyme not 
preincubated. 
preliminary examination in the present study, 
when chymotrypsin (1.3 pg) was incubated with 
1 mM H-(2R,3S)- V EPhe-Leu-OMe containing 
such a ring for 48 h, no hydrolysis of Ac-Tyr-OEt 
by the enzyme was observed (fig.3, curve a), while 
the enzyme was almost fully active when prein- 
cubated without inhibitor (fig.3, curve b). These 
results indicated that the enzyme was completely 
inactivated during incubation with the VPhe- 
peptide. When the preincubation period was omit- 
ted (fig.3, curve c) using the same peptide concen- 
tration, about 90% of the hydrolysis of 
Ac-Tyr-OEt occurred, showing only about 10% in- 
hibition. Since the active site of chymotrypsin con- 
tains aspartic acid residues (Asp-102 and 194), the 
carboxylate group of one of these residues may be 
placed for nucleophilic attack on the cyclopropane 
ring forming an ester at the active site and thereby 
causing irreversible inactivation of the enzyme. 
In conclusion, this work indicates that the incor- 
poration of 2,3-methanoamino acids into specific 
enzyme substrates may generate peptidic enzyme 
inhibitors. 
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